Pedro Mondéjar-López

Hospital Universitario Virgen de la Arrixaca

MedicineHealth Professions

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study”.

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study

American Journal of Respiratory and Critical Care Medicine(2022)10.1164/rccm.202202-0392oc

N/A

0DataRank · unranked

141 citations

Rossa Brugha, Silvia Gärtner, Julian Legg, Alexander Mœller, Pedro Mondéjar-López +19 more

Longitudinal transcriptional immune profiles and persistent wheezing in moderate‐to‐late preterm infants

Pediatric Allergy and Immunology(2024)10.1111/pai.14261

N/A

0DataRank · unranked

1 citations

Zhaohui Xu, Antonio Moreno, Olaia Sardón‐Prado, Teresa Rubí, Silvia Castillo +19 more